000 03824nam a2200445 c 4500
710 2 _aSpringerLink (Online service)
_9106996
999 _c117785
_d117785
_x1
001 117785
003 ES-MaUEC
005 20230102113827.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 191025s2019 gw a o |||| 0|eng d
020 _a9783030267360
024 7 _a10.1007/978-3-030-26736-0
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aQR342
_b2019 EB
245 0 0 _aPhage Therapy: A Practical Approach
_cedited by Andrzej Górski, Ryszard Międzybrodzki, Jan Borysowski.
250 _aFirst edition
264 1 _aCham, Switzerland
_bSpringer International Publishing
_c2019
300 _a1 recurso en línea (XV, 385 páginas)
_b26 ilustraciones, 24 ilustraciones a color
336 _2rdacontent
_aTexto
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aBiomedical and Life Sciences (Springer-11642)
505 0 _aPart I: Bacteriophages as antibacterialagents -- Chapter 1:Production of PhageTherapeutics and Formulations - InnovativeApproaches -- Chapter 2:Phagepharmacokinetics: relationship with administrationroute -- Chapter 3:BacterialResistance to Phage and itsImpact on Clinical Therapy -- Part II: Bacteriophages and the immune system -- Chapter 4:Phageinteraction with the mammalianimmune system -- Chapter 5:Humoralimmuneresponse to phage-basedtherapeutics -- Part III:Use of bacteriophages to combat bacterial infections -- Chapter 6:How to achieve a goodphage therapy clinical trial? -- Chapter 7: Perspectives on the RenewedInterest in the United States -- Chapter 8:Phage Therapy in Orthopaedic Implant-associated Infections -- Chapter 9:The use of bacteriophages in animalhealth and food protection -- Chapter 10:Combiningbacteriophages with otherantibacterialagents to combatbacteria -- Chapter 11: Phage therapy of infectious biofilms: Challenges and strategies -- Part IV:Phage therapy - regulatory and ethical aspects -- Chapter 12:Regulatory Considerations for Bacteriophage Therapy Products -- Chapter 13:Developing phagesintomedicines for Europe -- Chapter 14: Phagetherapy in Europe: Regulatory and intellectualpropertyprotectionissues -- Chapter 15:Ethics of phagetherapy -- Part V: Bacteriophage-derived antibacterial agents -- Chapter 16: NovelAlternative to Antibiotics.
520 3 _aThis book gives a detailed yet clear insight into the current state of the art of the therapeutic application of bacteriophages in different conditions. The authors bring in their practical expertise within their respective fields of expertise and provide an excellent overview of the potential and actual use of phage therapy. Topics like economic feasibility compared to traditional antibiotics and also regulatory issues are discussed in far detail. This new volume is therefore a valuable resource for individuals engaged in the medical application of novel phage therapies.
988 _aPrimersemestre_2020_BiomedLife
650 7 _aBacteriófagos
_2embne
_9671714
700 1 _aGórski, Andrzej
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aMiędzybrodzki, Ryszard
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aBorysowski, Jan
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
773 0 _tSpringer eBooks
776 0 8 _iPrinted edition:
_z9783030267353
776 0 8 _iPrinted edition:
_z9783030267377
776 0 8 _iPrinted edition:
_z9783030267384
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-26736-0
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
_n0
998 _b04/2020
_dz
_eh
_zSI